Table of Contents Author Guidelines Submit a Manuscript
Biochemistry Research International
Volume 2010 (2010), Article ID 361387, 5 pages
http://dx.doi.org/10.1155/2010/361387
Review Article

Hyperhomocysteinaemia in Behçet's Disease

Department of Internal Medicine, Fattouma Bourguiba University Hospital, 5000 Monastir, Tunisia

Received 18 January 2010; Accepted 15 February 2010

Academic Editor: R. J. Linhardt

Copyright © 2010 Amira Hamzaoui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Behçet, “Über residivierende aphtose, durch ein virus verursachte geschwüre am mund, am auge und den genitalen,” Dermatologische Wochenschrift, vol. 105, no. 36, pp. 1152–1157, 1937. View at Google Scholar
  2. B. Wechsler, L. T. H. Du, and E. Kieffer, “Cardiovascular manifestations of Behçet's disease,” Annales de Medecine Interne, vol. 150, no. 7, pp. 542–554, 1999. View at Google Scholar · View at Scopus
  3. K. Ozoran, N. Duzgun, A. Gurler, H. Tutkak, and G. Tokgoz, “Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease,” Scandinavian Journal of Rheumatology, vol. 24, no. 6, pp. 376–382, 1995. View at Google Scholar
  4. K. K. Hampton, M. A. Chamberlain, D. K. Menon, and J. A. Davies, “Coagulation and fibrinolytic activity in Behçet's disease,” Thrombosis and Haemostasis, vol. 66, no. 3, pp. 292–294, 1991. View at Google Scholar · View at Scopus
  5. S. Taysi, B. Demircan, N. Akdeniz, M. Atasoy, and R. A. Sari, “Oxidant/antioxidant status in men with Behçet's disease,” Clinical Rheumatology, vol. 26, no. 3, pp. 418–422, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. E. K. Hoogeveen, P. J. Kostense, and P. J. Kostense, “Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 1, pp. 133–138, 1998. View at Google Scholar
  7. C. J. Glueck, P. Shaw, J. E. Lang, T. Tracy, L. Sieve-Smith, and Y. Wang, “Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients,” American Journal of Cardiology, vol. 75, no. 2, pp. 132–136, 1995. View at Publisher · View at Google Scholar · View at Scopus
  8. O. Cetin, S. Bekpinar, Y. Ünlucerci, A. Turkmen, Ç. Bayram, and T. Ulutin, “Hyperhomocysteinemia in chronic renal failure patients: relation to tissue factor and platelet aggregation,” Clinical Nephrology, vol. 65, no. 2, pp. 97–102, 2006. View at Google Scholar · View at Scopus
  9. P. M. Ueland and H. Refsum, “Plasma homocysteine, a risk factor for premature vascular disease. Plasma levels in healthy persons; during pathologic conditions and drug therapy,” Nordisk medicin, vol. 104, no. 11, pp. 293–298, 1989. View at Google Scholar
  10. M. Shinawi, “Hyperhomocysteinemia and cobalamin disorders,” Molecular Genetics and Metabolism, vol. 90, no. 2, pp. 113–121, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. S. L. Morgan, J. E. Baggott, J. Y. Lee, and G. S. Alarcón, “Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention,” Journal of Rheumatology, vol. 25, no. 3, pp. 441–446, 1998. View at Google Scholar
  12. A. S. Wierzbicki, “Homocysteine and cardiovascular disease: a review of the evidence,” Diabetes and Vascular Disease Research, vol. 4, no. 2, pp. 143–149, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. K. Aksu, N. Turgan, and N. Turgan, “Hyperhomocysteinaemia in Behçet's disease,” Rheumatology, vol. 40, no. 6, pp. 687–690, 2001. View at Google Scholar · View at Scopus
  14. Y. J. Lee, S. W. Kang, and S. W. Kang, “Coagulation parameters and plasma total homocysteine levels in Behçet's disease,” Thrombosis Research, vol. 106, no. 1, pp. 19–24, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Er, C. Evereklioglu, T. Cumurcu, Y. Türköz, E. Özerol, K. Şahin, and S. Daganay, “Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behçet's disease,” British Journal of Ophthalmology, vol. 86, no. 6, pp. 653–657, 2002. View at Publisher · View at Google Scholar
  16. C. Korkmaz, B. Bozan, M. Kosar, F. Sahin, and Z. Gülbas, “Is there an association of plasma homocysteine levels with vascular involvement in patients with Behçet's syndrome?” Clinical and Experimental Rheumatology, vol. 20, no. 4, pp. S30–S34, 2002. View at Google Scholar
  17. H. Houman, M. Feki, and M. Feki, “Does hyperhomocysteinemia increase the risk of thrombosis in Behçet's disease?” Advances in Experimental Medicine and Biology, vol. 528, pp. 413–417, 2003. View at Google Scholar
  18. A. Ateş, O. Aydintuğ, U. Olmez, N. Düzgün, and M. Duman, “Serum homocysteine level is higher in Behçet's disease with vascular involvement,” Rheumatology International, vol. 25, no. 1, pp. 42–44, 2005. View at Google Scholar
  19. Z. Yesilova, S. Pay, and S. Pay, “Hyperhomocysteinemia in patients with Behçet's disease: is it due to inflammation or therapy?” Rheumatology International, vol. 25, no. 6, pp. 423–428, 2005. View at Publisher · View at Google Scholar · View at PubMed
  20. R. Ozdemir, I. Barutcu, and I. Barutcu, “Vascular endothelial function and plasma homocysteine levels in Behçet's disease,” American Journal of Cardiology, vol. 94, no. 4, pp. 522–525, 2004. View at Publisher · View at Google Scholar · View at PubMed
  21. T. Sarican, H. Ayabakan, S. Turkmen, V. Kalaslioglu, F. Baran, and N. Yenice, “Homocysteine: an activity marker in Behçet's disease?” Journal of Dermatological Science, vol. 45, no. 2, pp. 121–126, 2007. View at Publisher · View at Google Scholar · View at PubMed
  22. Y. Özkan, S. Yardim-Akaydin, A. Sepici, B. Engin, V. Sepici, and B. Şimşek, “Assessment of homocysteine, neopterin and nitric oxide levels in Behçet's disease,” Clinical Chemistry and Laboratory Medicine, vol. 45, no. 1, pp. 73–77, 2007. View at Publisher · View at Google Scholar · View at PubMed
  23. M. Feki, H. Houman, and H. Houman, “Hyperhomocysteinaemia is assocaited with uveitis but not with deep venous thrombosis in Behçet's disease,” Clinical Chemistry and Laboratory Medicine, vol. 42, no. 12, pp. 1417–1423, 2004. View at Publisher · View at Google Scholar · View at PubMed
  24. K. S. Woo, P. Chook, and P. Chook, “Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans,” Circulation, vol. 96, no. 8, pp. 2542–2544, 1997. View at Google Scholar
  25. K. Pietrzik, “Homocysteine as a cardiovascular marker and risk factor,” Clinical Research in Cardiology, vol. 95, no. 6, pp. 28–33, 2006. View at Publisher · View at Google Scholar · View at PubMed
  26. R. Obeid, A. McCaddon, and W. Herrmann, “The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric diseases,” Clinical Chemistry and Laboratory Medicine, vol. 45, no. 12, pp. 1590–1606, 2007. View at Publisher · View at Google Scholar · View at PubMed
  27. G. Sottilotta, V. Oriana, and V. Oriana, “Role of hyperhomocystinemia in retinal vascular occlusive disease,” Clinical and Applied Thrombosis/Hemostasis, vol. 13, no. 1, pp. 104–107, 2007. View at Publisher · View at Google Scholar · View at PubMed
  28. J. D. Finkelstein, “The metabolism of homocysteine: pathways and regulation,” European Journal of Pediatrics, vol. 157, no. 2, pp. S40–S44, 1998. View at Google Scholar
  29. E. Çalikoǧlu, M. Öztaş, N. Şengül, B. Adam, and M. A. Gürer, “Serum homocysteine level in Behçet's disease,” Haematologia, vol. 32, no. 3, pp. 219–224, 2002. View at Publisher · View at Google Scholar
  30. M. Okka, M. Öztürk, M. C. Korkar, N. Bavbek, Y. Rasier, and K. Gunduz, “Plasma homocysteine level and uveitis in Behçt's disease,” Israel Medical Association Journal, vol. 4, no. 11, pp. 931–934, 2002. View at Google Scholar
  31. G. J. Hankey and J. W. Eikelboom, “Homocysteine and vascular disease,” The Lancet, vol. 354, no. 9176, pp. 407–413, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Aflaki, M. Mehryar, M.-A. Nazarinia, Z. Habibagahi, A. Rajaee, and G. Ranjbar-Omrani, “The relation between serum homocysteine level and eye involvement in Behçet's disease,” Archives of Iranian Medicine, vol. 11, no. 6, pp. 625–628, 2008. View at Google Scholar
  33. M. Cahill, M. Karabatzaki, and M. Karabatzaki, “Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease,” British Journal of Ophthalmology, vol. 84, no. 2, pp. 154–157, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. J. M. Ricart, A. Vayá, and A. Vayá, “Thrombophilic risk factors and homocysteine levels in Behçt's disease in eastern Spain and their association with thrombotic events,” Thrombosis and Haemostasis, vol. 95, no. 4, pp. 618–624, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. S. P. K. Durmazlar, A. Akgul, and F. Eskioglu, “Homocysteine may involve in the pathogenesis of Behçet's disease by inducing inflammation,” Mediators of Inflammation, vol. 2008, Article ID 407972, 9 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
  36. M. Gönül, Ü. Gül, C. Kilinç, S. K. Çakmak, S. Soylu, and A. Kiliç, “Homocysteine levels in patients with Behçet's disease and patients with recurrent aphthous stomatitis,” Clinical Rheumatology, vol. 28, no. 10, pp. 1153–1156, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. R. Sandikci, S. Turkmen, G. Guvenen et al., “Lipid peroxidation and antioxidant defence system in patients with active or inactive Behçet's disease,” Acta Dermato-Venereologica, vol. 83, no. 5, pp. 342–346, 2003. View at Google Scholar
  38. S. Buldanlioglu, S. Turkmen, H. B. Ayabakan, N. Yenice, M. Vardar, S. Dogan, and E. Mercan, “Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Behçet's disease,” British Journal of Dermatology, vol. 153, no. 3, pp. 526–530, 2005. View at Publisher · View at Google Scholar · View at PubMed
  39. P. C. Harpel, X. Zhang, and W. Borth, “Homocysteine and hemostasis: pathogenetic mechanisms predisposing to thrombosis,” Journal of Nutrition, vol. 126, supplement 4, pp. 1285–1289, 1996. View at Google Scholar · View at Scopus